Alendronate sodium/vitamin D3 combination tablet versus calcitriol for osteoporosis in Chinese postmenopausal women: a 6-month, randomized, open-label, active-comparator-controlled study with a 6-month extension

Z L Zhang, E Y Liao, W B Xia, H Lin, Q Cheng, L Wang, Y Q Hao, D C Chen, H Tang, Y De Peng, L You, L He, Z H Hu, C L Song, F Wei, J Wang, L Zhang, A C Santora, Z L Zhang, E Y Liao, W B Xia, H Lin, Q Cheng, L Wang, Y Q Hao, D C Chen, H Tang, Y De Peng, L You, L He, Z H Hu, C L Song, F Wei, J Wang, L Zhang, A C Santora

Abstract

This study compares efficacy of ALN/D5600 versus that of calcitriol in osteoporotic Chinese postmenopausal women. ALN/D5600 produced greater bone mineral density (BMD) increases, greater bone turnover marker decreases, and less vitamin D insufficiency. This study provided detailed clinical information regarding ALN/D5600 treatment versus calcitriol 0.25 μg/day. The study did not evaluate fracture risk.

Introduction: The aim of this study is to investigate efficacy of alendronate 70 mg/vitamin D3 5600 IU combination tablets (ALN/D5600) versus calcitriol in osteoporotic Chinese postmenopausal women.

Methods: This study is a 6-month, randomized, open-label, active-comparator study with 6-month extension (clinicaltrials.gov number NCT01350934) in postmenopausal women aged >55 years with osteoporosis (low bone mineral density (BMD) with/without prior fragility fracture). Patients were randomized to ALN/D5600 once weekly or calcitriol 0.25 μg daily. The primary efficacy end point of the base study was percent change from baseline in lumbar spine BMD (month 6). Hypercalcemia and hypercalciuria were safety events of special interest.

Results: A total of 219 patients (ALN/D5600 n = 111, calcitriol n = 108) were randomized. Baseline characteristics were similar, 30.3 % baseline 25-hydroxyvitamin D (25(OH)D) ≤15 ng/mL. At months 6 and 12, changes in lumbar spine BMD from baseline were 3.5 versus 1.6 % and 5.2 versus 2.3 % for ALN/D5600 versus calcitriol (between-group differences p < 0.001), respectively. Between-group differences for ALN/D5600 versus calcitriol were significant (p < 0.001) at months 6 and 12 for change from baseline in procollagen type 1 N-terminal propeptide (-59.1 versus -16.8 %, -68.1 versus -17.0 %) and serum C-telopeptides (-79.2 versus -27.2 %, -76.2 versus -24.2 %). Drug-related adverse events (AEs) and discontinuations due to drug-related AEs occurred in 15 (14.0 %) versus 8 (7.4 %) patients and 3 (2.8 %) versus 0 patients in the ALN/D5600 and calcitriol group, respectively. Hypercalciuria 12-month incidence (24-h urine Ca >300 mg) was 8.4 (ALN/D5600) versus 13.9 % (calcitriol) (p > 0.05). One patient (calcitriol) had hypercalcemia.

Conclusions: ALN/D5600 produced greater increases in lumbar spine BMD and greater decreases in bone turnover markers versus calcitriol in osteoporotic Chinese women. It is not known whether the greater increase in BMD results in fewer fractures. ALN/D5600 was generally well tolerated in Chinese patients.

Figures

Fig. 1
Fig. 1
Patient disposition. ALN/D5600 combination tablet of alendronate 70 mg plus vitamin D3 5600 IU once weekly
Fig. 2
Fig. 2
Percent change from baseline in BMD at a the lumbar spine, b total hip, c femoral neck, d and trochanter, at months 6 and 12 (FAS). ALN/D5600 combination tablet of alendronate 70 mg plus vitamin D3 5600 IU once weekly, BMD bone mineral density, FAS full analysis set, SE standard error
Fig. 3
Fig. 3
Percent change from baseline in bone turnover markers: a P1NP and b s-CTx (FAS). ALN/D5600 combination tablet of alendronate 70 mg plus vitamin D3 5600 IU once weekly, CI confidence interval, FAS full analysis set, LS least squares, P1NP procollagen of type 1 N-terminal propeptide, s-CTx C-telopeptides of type 1 collagen
Fig. 4
Fig. 4
Changes from baseline in serum 25(OH)D concentrations after treatment with ALN/D5600 or calcitriol (FAS). ALN/D5600 combination tablet of alendronate 70 mg plus vitamin D3 5600 IU once weekly, FAS full analysis set, SE standard error, 25(OH)D 25-hydroxy vitamin D. *Post hoc analysis: two-sample independent t test without adjustments for covariates

References

    1. International Osteoporosis Foundation (2013) The Asia-Pacific regional audit. Epidemiology, costs & burden of osteoporosis in 2013. . Accessed 31 March 2015
    1. National Bureau of Statistics of China (2010) 2010 Population Census of the People’s Republic of China. . Accessed 31 March 2015
    1. Wang Y, Tao Y, Hyman ME, Li J, Chen Y. Osteoporosis in China. Osteoporos Int. 2009;20:1651–1662. doi: 10.1007/s00198-009-0925-y.
    1. National Osteoporosis Foundation . Clinician’s guide to prevention and treatment of osteoporosis. Washington: National Osteoporosis Foundation; 2013.
    1. Wat WZ, Leung JY, Tam S, Kung AW. Prevalence and impact of vitamin D insufficiency in southern Chinese adults. Ann Nutr Metab. 2007;51:59–64. doi: 10.1159/000100822.
    1. Zhang W, Stoecklin E, Eggersdorfer M. A glimpse of vitamin D status in Mainland China. Nutrition. 2013;29:953–957. doi: 10.1016/j.nut.2013.01.010.
    1. Zhen D, Liu L, Guan C, Zhao N, Tang X. High prevalence of vitamin D deficiency among middle-aged and elderly individuals in northwestern China: its relationship to osteoporosis and lifestyle factors. Bone. 2015;71:1–6. doi: 10.1016/j.bone.2014.09.024.
    1. Yan Y, Wang W, Zhu H, Li M, Liu J, Luo B, Xie H, Zhang G, Li F. The efficacy and tolerability of once-weekly alendronate 70 mg on bone mineral density and bone turnover markers in postmenopausal Chinese women with osteoporosis. J Bone Miner Metab. 2009;27:471–478. doi: 10.1007/s00774-009-0057-7.
    1. Miettinen O, Nurminen M. Comparative analysis of two rates. Stat Med. 1985;4:213–226. doi: 10.1002/sim.4780040211.
    1. Liberman UA, Weiss SR, Broll J, Minne HW, Quan H, Bell NH, Rodriguez-Portales J, Downs RW, Jr, Dequeker J, Favus M. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med. 1995;333:1437–1443. doi: 10.1056/NEJM199511303332201.
    1. Pols HA, Felsenberg D, Hanley DA, Stepan J, Munoz-Torres M, Wilkin TJ, Qin-sheng G, Galich AM, Vandormael K, Yates AJ, Stych B. Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Fosamax International Trial Study Group. Osteoporos Int. 1999;9:461–468. doi: 10.1007/PL00004171.
    1. Schnitzer T, Bone HG, Crepaldi G, Adami S, McClung M, Kiel D, Felsenberg D, Recker RR, Tonino RP, Roux C, Pinchera A, Foldes AJ, Greenspan SL, Levine MA, Emkey R, Santora AC, Kaur A, Thompson DE, Yates J, Orloff JJ. Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group. Aging (Milano) 2000;12:1–12.
    1. Rosen CJ, Hochberg MC, Bonnick SL, McClung M, Miller P, Broy S, Kagan R, Chen E, Petruschke RA, Thompson DE, de Papp AE. Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study. J Bone Miner Res. 2005;20:141–151. doi: 10.1359/JBMR.040920.
    1. Reid DM, Hosking D, Kendler D, Brandi ML, Wark JD, Weryha G, Marques-Neto JF, Gaines KA, Verbruggen N, Melton ME. Alendronic acid produces greater effects than risedronic acid on bone density and turnover in postmenopausal women with osteoporosis: results of FACTS-international. Clin Drug Investig. 2006;26:63–74. doi: 10.2165/00044011-200626020-00002.
    1. Sambrook PN, Geusens P, Ribot C, Solimano JA, Ferrer-Barriendos J, Gaines K, Verbruggen N, Melton ME. Alendronate produces greater effects than raloxifene on bone density and bone turnover in postmenopausal women with low bone density: results of EFFECT (Efficacy of FOSAMAX versus EVISTA Comparison Trial) International. J Intern Med. 2004;255:503–511. doi: 10.1111/j.1365-2796.2004.01317.x.
    1. Luckey M, Kagan R, Greenspan S, Bone H, Kiel RD, Simon J, Sackarowitz J, Palmisano J, Chen E, Petruschke RA, de Papp AE. Once-weekly alendronate 70 mg and raloxifene 60 mg daily in the treatment of postmenopausal osteoporosis. Menopause. 2004;11:405–415. doi: 10.1097/01.GME.0000119981.77837.1F.
    1. Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, Palermo L, Prineas R, Rubin SM, Scott JC, Vogt T, Wallace R, Yates AJ, LaCroix AZ. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA. 1998;280:2077–2082. doi: 10.1001/jama.280.24.2077.
    1. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet. 1996;348:1535–1541. doi: 10.1016/S0140-6736(96)07088-2.
    1. Tilyard MW, Spears GF, Thomson J, Dovey S. Treatment of postmenopausal osteoporosis with calcitriol or calcium. N Engl J Med. 1992;326:357–362. doi: 10.1056/NEJM199202063260601.
    1. Holick MF. Vitamin D deficiency. N Engl J Med. 2007;357:266–281. doi: 10.1056/NEJMra070553.
    1. Society of Osteoporosis and Bone Mineral Research Chinese Medical Association Guidelines for diagnosis and treatment of primary osteoporosis. Chin J Osteoporos Bone Miner Res. 2011;4:2–17.
    1. Rizzoli R, Boonen S, Brandi ML, Bruyere O, Cooper C, Kanis JA, Kaufman JM, Ringe JD, Weryha G. Vitamin D supplementation in elderly or postmenopausal women: a 2013 update of the 2008 recommendations from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) Curr Med Res Opin. 2013;29:305–313. doi: 10.1185/03007995.2013.766162.
    1. Binkley N, Ringe JD, Reed JI, Ljunggren O, Holick MF, Minne HW, Liu M, Lamotta A, West JA, Santora AC. Alendronate/vitamin D3 70 mg/2800 IU with and without additional 2800 IU vitamin D3 for osteoporosis: results from the 24-week extension of a 15-week randomized, controlled trial. Bone. 2009;44:639–647. doi: 10.1016/j.bone.2008.05.002.
    1. Ralston SH, Binkley N, Boonen S, Kiel DP, Reginster JY, Roux C, Chen L, Rosenberg E, Santora A. Randomized trial of alendronate plus vitamin D3 versus standard care in osteoporotic postmenopausal women with vitamin D insufficiency. Calcif Tissue Int. 2011;88:485–494. doi: 10.1007/s00223-011-9482-4.
    1. Hossein-nezhad A, Holick MF. Vitamin D for health: a global perspective. Mayo Clin Proc. 2013;88:720–755. doi: 10.1016/j.mayocp.2013.05.011.
    1. Olmos JM, Hernandez JL, Llorca J, Nan D, Valero C, Gonzalez-Macias J. Effects of 25-hydroxyvitamin D3 therapy on bone turnover markers and PTH levels in postmenopausal osteoporotic women treated with alendronate. J Clin Endocrinol Metab. 2012;97:4491–4497. doi: 10.1210/jc.2012-2999.
    1. Ishijima M, Sakamoto Y, Yamanaka M, Tokita A, Kitahara K, Kaneko H, Kurosawa H. Minimum required vitamin D level for optimal increase in bone mineral density with alendronate treatment in osteoporotic women. Calcif Tissue Int. 2009;85:398–404. doi: 10.1007/s00223-009-9295-x.
    1. Antoniucci DM, Vittinghoff E, Palermo L, Black DM, Sellmeyer DE. Vitamin D insufficiency does not affect response of bone mineral density to alendronate. Osteoporos Int. 2009;20:1259–1266. doi: 10.1007/s00198-008-0799-4.
    1. Roux C, Binkley N, Boonen S, Kiel DP, Ralston SH, Regnister JY, Pong A, Rosenberg E, Santora A. Vitamin D status and bone mineral density changes during alendronate treatment in postmenopausal osteoporosis. Calcif Tissue Int. 2014;94:153–157. doi: 10.1007/s00223-013-9763-1.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe